ࡱ> \^]5@ p!bjbj22 2:XX@^^^^84.,<f|( H  I<K<K<K<K<K<K<$>RAxo<R&- ^ R&R&o<^( <'''R&|I<'R&I<''F(9;Z PL&@m:<4<0<:A'A(;^^;A;p rq"'y#M$ o<o< $ 'THE PAEDIATRIC SOCIETY OF NEW ZEALAND Secretariat: Email: Denise Tringham P O Box 22 234 Wellington Tel: (04) 938 4827 Fax: (04) 976 4827  HYPERLINK "mailto:psnz@paradise.net.nz" psnz@paradise.net.nz   Position Statement Expanded Newborn Metabolic Screening Expanded newborn screening refers to the use of tandem mass spectrometry (MSMS) to increase the range of newborn metabolic screening (Guthrie testing) from the current seven disorders to over 30. MSMS is a laboratory technique which can simultaneously measure a wide range of chemicals in a small amount of blood sufficiently quickly and cheaply to make it suitable as a screening technology. The Paediatric Society of New Zealand believes: Metabolic disease is currently under diagnosed in New Zealand and the introduction of expanded newborn screening will significantly improve this. Expanded Newborn Screening using MSMS technology fulfils the established criteria used to evaluate a screening programme. The conditions together represent a significant health problem. Tandem mass spectrometry provides a simple, safe, reliable, sensitive and specific test for these disorders. Treatment exists for most conditions detectable by MSMS and screening will only be done for conditions for which treatment or intervention exists. The adverse effects from expanded newborn screening are minimal and similar to those found with existing newborn screening. Expanded newborn screening aligns with national policies on increasing preventive health and screening. Expanded newborn screening could help close the gap between Maori/Pacific and non-Maori in diagnosis of metabolic disease. The Paediatric Society of New Zealand notes: A number of publications in the international paediatric literature have outlined both the clinical efficacy and cost effectiveness of expanded newborn screening  There is an existing newborn metabolic screening infrastructure in New Zealand, involving lead maternity carers, hospital paediatricians and nurses, the National Testing Centre and the National Metabolic Service around which expanded newborn screening could be based. The introduction of expanded newborn screening will result in a reduction in mortality of approximately 3-5 lives per year. Another 3-5 children will survive with considerably reduced morbidity. The purchase of tandem mass spectrometry technology will greatly facilitate the development of a metabolic laboratory of international standard in New Zealand. This will reduce turnaround times facilitating quicker diagnosis and treatment and enable more appropriate use of specialist referral laboratories in Australia. Tandem mass spectrometry will also allow for improved investigation and monitoring of New Zealanders with known or suspected metabolic diseases. The start up cost of expanded newborn screening, including the purchase of a tandem mass spectrometer, is $660 000 while the subsequent annual costs are estimated at $170 000. These costs are extremely favourable when compared to screening programmes for adults. The sensitivity and specificity of expanded screening are dependent on the algorithms and cutoffs used, and the severity of disease to be detected. Predicting from established programs and 2002 New Zealand data the increase from 7 disorders to 37 will change the false positive rate from about 0.40% to 0.55%. A New Zealand cost benefit analysis of screening for the fatty acid oxidation disorders suggests it will be highly cost effective with a cost per death avoided of $11,500 and the cost per life year gained of $590 All Australian, most North American and many European newborns receive the benefit of expanded newborn screening. Screening is recommended by the Newborn Screening Committee of the Human Genetics Society of Australasia and the RACP Division of Paediatrics. The Paediatric Society of New Zealand recommends: The Ministry of Health requests the committee for Newborn Screening consider the evidence related to the benefits of expanded newborn screening with a view to the purchase of a tandem mass spectrometer That in establishing the need for such a service appropriate resources are made available for treatment of affected infants' That funding is allocated for the ongoing screening including quality initiatives and audit of the service. The Paediatric Society of New Zealand recommends its members to: Encourage the development of expanded newborn screening and the purchase of tandem mass spectrometry technology. Continue to support the development of tertiary services. Familiarise themselves with the basic uses of tandem mass spectrometry in childhood disease; its advantages and limitations in regard to both the screening of newborns and in the investigation and monitoring of children with suspected metabolic disease. Health of our children: Wealth of our nation Page  PAGE 2 of  NUMPAGES 3 October 2004 Review October 2006 Callum Wilson/Dianne Webster  Dr Dianne Webster, unpublished.  The current newborn screening programme has widespread coverage and high acceptance amongst the Maori and Pacific communities. There is, as yet unpublished, evidence (Dr Callum Wilson, National Metabolic Service) that certain metabolic diseases have high prevalence in the Maori and Pacific communities and that many of these children are not being diagnosed with current practices.  Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348:23042312.  Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, Stanley CA. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. 2003 Nov;112(5):1005-15  Dr Callum Wilson. Figures based on analysis of international results. Lives saved come principally for the fatty acid oxidation disorders whereby children usually die suddenly and unexpectedly while the reduced morbidity group also comprises the protein disorders (organic acidemias and urea cycle disorders) whereby currently the children often survive albeit with significant neurological impairment.  Milne RJ, Slack A, Cumming J. Economic Evaluation of a Tandem Mass Spectrometer to Screen for Fatty Acid Oxidation Disorders in Neonates. Report commissioned for the National Testing Centre, August 2002. '()BC   # $ & ' ( ) * + , P 㵥|pkgYgE&h3H59:>*CJOJQJ^JaJjh3HUmHnHuh3H h3H5h3H0JCJOJQJ*jh3HB*CJOJQJUph$jh3HB*CJOJQJUphh3H5B*CJOJQJphh3HB*CJOJQJphh3H5B*CJ(OJQJphh3H5B*CJ$OJQJphh3H5OJQJ%jh3H5OJQJUmHnHu()6789:<C`| $ $Ifa$$ !Sn#$Ifa$$ !n#'$If^'`a$$ !Sn#$Ifa$$ !Sn#$Ifa$  x$If  $If@o!' ( ) , ? d e lfd^^\\\$@&a$ !pkd$$IfT\ K2%?%aT$ !n#$Ifa$$ !Sn#$Ifa$ P Z d  ( 0 1  N O m n   r s ǶǶǨ~l~UDDnjnjnj hE/h?CJOJQJ^JaJ-jhE/h3H0JCJOJQJU^JaJ#h3H59:CJOJQJ^JaJh3HCJOJQJ^JaJh@{CJOJQJ^JaJh CJOJQJ^JaJhL&CJOJQJ^JaJ hE/hB,:CJOJQJ^JaJ hE/h3HCJOJQJ^JaJ&h3H59:>*CJOJQJ^JaJ&h?59:>*CJOJQJ^JaJ  / o o TUz{OPX & F & F & F@&s RSpudmvw jnvhZh4CJOJQJ^JaJh BjCJOJQJ^JaJ#hE/h3HCJOJQJ\^JaJ#h3H59:CJOJQJ^JaJh3HCJOJQJ^JaJ-jhE/h3H0JCJOJQJU^JaJ hE/hB,:CJOJQJ^JaJ hE/h?CJOJQJ^JaJh@{CJOJQJ^JaJ hE/h3HCJOJQJ^JaJ#nKVWV]deghifghӴӣӣӌӣzl^Plh3HCJOJQJ^JaJhaCJOJQJ^JaJh*YCJOJQJ^JaJ#h3H59:CJOJQJ^JaJ-jhE/h3H0JCJOJQJU^JaJ hE/hB,:CJOJQJ^JaJ hE/hg CJOJQJ^JaJh3HCJOJQJ^JaJ hE/h3HCJOJQJ^JaJh4CJOJQJ^JaJh BjCJOJQJ^JaJXYfghihQRSAB@m$a$gd2.$a$ & Fh^hgd*Y & F@& & FgdB,:OPQRS?@@rsyz{|ͼ}ͼtftfWftftfWftNtNh2.5CJaJh2.5CJaJmHnHujhQg5CJUaJhQg5CJaJ#h3H59:CJOJQJ^JaJh3HCJOJQJ^JaJ hE/h*YCJOJQJ^JaJh3HCJOJQJ^JaJ hE/h?CJOJQJ^JaJ hE/h3HCJOJQJ^JaJ h."h3HCJOJQJ^JaJ h."hzCJOJQJ^JaJt  n!o!p! & F@&$a$$a$gd2. tu    n!o!p! hE/h3HCJOJQJ^JaJ hQgCJjhQg0JCJU hQg\h2.mH sH hQgmH sH jhQg0JUh2.hQg01hBP. A!"#n$n% DyK psnz@paradise.net.nzyK 8mailto:psnz@paradise.net.nz$$If!vh55?55#v#v?#v#v:V %55?554aT@@@ NormalCJ_HaJmH sH tH DA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k(No List HH  Balloon TextCJOJQJ^JaJ<+@<  Endnote TextCJaJ>*@> Endnote ReferenceH*>B@"> Body TextaJmH sH tH D @2D Footer  !aJmH sH tH RYBR  Document Map-D M OJQJ^JR@RR Header$ !a$5CJOJQJaJtH 0U@a0 Hyperlink>*B*Nv dp$F:p:()6789:<C`|'(),?de /ooTUz { O P X Y fghihQRSAB@mt nq00000000000000000000000?0?0?00 00 0 0 0 0 00 00 0000 00 00 00 00 00 00 00 00 0000i 0i 0i 0i0i0i00S 0S0S 0S0S 0S@0@0@0p@0@0@00`@0@0@0@0@0@00x=\()6789:<C`|'(),?de /ooTUz { O P X Y fghihQR@mtq00000000000000000000 000H0H0H00 00 0 0 0 0 00 00 0000 00 00 00 00 00 00 00 00 0000r 0r 0r 0q 0q 0r$Oy00@0Oy00 0r{00 {00 0 N\P s np! Xp!o!#pX29;@KM!8 @@(  TB  c $DgTB  c $DԔn    C"8  BCqDELFVSS?-;lbn2qk\D@ORQ8Q* gw  W <b14\5q<O>B 1 8w1N/ : f 1  y?  u M  4  `6U:LsNA_cknkAehS)8Z' sZ' *b?@`   TB CnDExFf%Ip,0A  K *   8 h  L  D kk nPn&k X>>@@`h H2  #   H2  # ' B S  ?)*pLu"u"u OLE_LINK1 OLE_LINK2 _Hlk31519747q,,,quT uu uu$J u!*uܱu< ulI uL u4K uH uG u u u ul u\ uD u u<_0uu u<u| ȕmm  SS    mmq     ''tw^^  & & xxq 8*urn:schemas-microsoft-com:office:smarttagsCity;*urn:schemas-microsoft-com:office:smarttagsaddress:*urn:schemas-microsoft-com:office:smarttagsStreetB*urn:schemas-microsoft-com:office:smarttagscountry-regionV*urn:schemas-microsoft-com:office:smarttagsplacehttp://www.5iantlavalamp.com/  @v}$,qQR@ q33)C,?0 {  QR@mr|,mq@q CallumWVeronica CaseykevinpkevinpRoland BroadbentDianneW7aa+X܏'&@ll@E6^|PHa|R>ub?4wr ^`hH. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h hh^h`hH.h 88^8`hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h88^8`OJQJo(hH ^`hH.  L ^ `LhH.   ^ `hH. xx^x`hH. HLH^H`LhH. ^`hH. ^`hH. L^`LhH.hhh^h`OJQJo(hHh 88^8`o(hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.+PHa>u'&4w7aal@E60                                                               Y)pg ?L&2.E/B,:3HNVQg Bj4 *YU."@{F$zaa))C'(q"@QQԞBQQpp@UnknownG: Times New Roman5Symbol3& : Arial?Bodoni BookEAGaramond BoldA& Arial Narrow5& zaTahomaG& Eras Medium ITC"qh誊誊ゃFa "a "!n4d77 3QH?$Position StatementCallumWVeronica Casey(       Oh+'0 ( D P \ ht|Position StatementosiCallumWallall Normal.dotaVeronica Caseye2roMicrosoft Word 10.0@F#@ @^@^a՜.+,D՜.+,\ hp  Auckland Healthcare Servicesn" 7A Position Statement Title P _PID_HLINKS_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_PreviousAdHocReviewCycleID_ReviewingToolsShownOnceAp3Dmailto:psnz@paradise.net.nz3Newborn position statementvcasey@xtra.co.nztaVeronica Caseynero  !"#$%'()*+,-./0123456789:;<=>?@ABCDEFHIJKLMNPQRSTUVYRoot Entry F/[Data 1Table&AWordDocument2:SummaryInformation(GDocumentSummaryInformation8OCompObjj  FMicrosoft Word Document MSWordDocWord.Document.89qRoot Entry F@@ZaData 1Table&AWordDocument2:  !"#$%'()*+,-./0123456789:;<=>?@ABCDEFHIJKLMN`_  _PID_HLINKS_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_PreviousAdHocReviewCycleID_ReviewingToolsShownOnceAp3Dmailto:psnz@paradise.net.nz@3Y3Position Statementvcasey@xtra.co.nzVeronica CaseySummaryInformation(GDocumentSummaryInformation8|CompObjj  FMicrosoft Word Document MSWordDocWord.Document.89q՜.+,D՜.+,\ hp  Auckland Healthcare Servicesn" 7A Position Statement Title H  Paediatric Society of New Zealand: Position Statements
Skip to main content

Position Statements

From time to time the Society will produce a Position Statement - a statement that presents the Society's opinion about a particular child health issue in the form of a detailed report which explains and/or recommends a particular course of action.  

Sorry, the requested view was not found.

The technical reason is: No template was found. View could not be resolved for action "download" in class "Ocular\Filemanager\Controller\FileController".